Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications

Autores
Cardinali, Daniel Pedro; Cano Barquilla, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión enviada
Descripción
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.
Fuente
Neuroendocrinology 2011, 93 (3)
Materia
MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1619
Acceder
id RIUCA_f3e493fcb4d8d80781f2e100a6e89c8d
oai_identifier_str oai:ucacris:123456789/1619
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Melatonin and the metabolic syndrome : physiopathologic and therapeutical implicationsCardinali, Daniel PedroCano Barquilla, PilarJiménez Ortega, VanesaEsquifino, Ana I.MELATONINARITMO CIRCADIANOSINDROME METABOLICOAGONISTASFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; ArgentinaFil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaFil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaFil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaAbstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.Karger Publishers2011info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16190028-3835 (Print)1423-0194 (Online)10.1159/000324699Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619Neuroendocrinology 2011, 93 (3)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1619instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:19.987Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
spellingShingle Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
Cardinali, Daniel Pedro
MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
title_short Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_full Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_fullStr Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_full_unstemmed Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_sort Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author_role author
author2 Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author2_role author
author
author
dc.subject.none.fl_str_mv MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
topic MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
dc.description.none.fl_txt_mv Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.
description Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
publishDate 2011
dc.date.none.fl_str_mv 2011
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/submittedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str submittedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1619
0028-3835 (Print)
1423-0194 (Online)
10.1159/000324699
Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619
url https://repositorio.uca.edu.ar/handle/123456789/1619
identifier_str_mv 0028-3835 (Print)
1423-0194 (Online)
10.1159/000324699
Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Karger Publishers
publisher.none.fl_str_mv Karger Publishers
dc.source.none.fl_str_mv Neuroendocrinology 2011, 93 (3)
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330553368576
score 13.070432

Publicaciones similares